New drug cocktail aims to tackle Hard-to-Treat breast cancer

NCT ID NCT06555068

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests an experimental drug called HRS-6209 in combination with several other breast cancer treatments (fulvestrant, letrozole, HRS-8080, or HRS-1358) for people with advanced breast cancer that cannot be surgically removed or has spread. The trial includes two stages: first finding a safe dose, then checking how well the combinations shrink tumors. Participants are women aged 18-75 whose cancer has not responded to standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called HRS-6209 combined with other breast cancer treatments
What this could lead to: If successful, this could provide a new treatment option for people with advanced breast cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial, so the drug combination may not prove effective or could cause unexpected side effects. Results are preliminary and need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates